Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
PDAC - Pancreatic Ductal Adenocarcinoma

About this trial
This is an interventional diagnostic trial for PDAC - Pancreatic Ductal Adenocarcinoma focused on measuring Pancreas, Pancreatic cancer, CT perfusion, Histopathology, Imaging Biomarker
Eligibility Criteria
Inclusion Criteria: Clinical suspicion of pancreatic cancer 18 years and older written (signed and dated) informed consent Exclusion Criteria: Contra-indications to undergo CT (due to untreatable contrast allergy or renal function impairment) Previous treatment for pancreatic cancer Concomitant malignancies. Subjects with prior malignancies must be disease-free for at least 5 years Insufficient command of the Dutch language to be able to understand the patient information
Sites / Locations
- Radboud University Medical HospitalRecruiting
Arms of the Study
Arm 1
Experimental
CT Perfusion
All patients will receive a baseline CT Perfusion scan. A subgroup of patients with chemotherapy treatment will receive a follow-up CT Perfusion after 3 months.